ArticleCureus2025
In Silico Molecular Docking Analysis of Valproic Acid as an Inhibitor of Bruton's Tyrosine Kinase: Potential Drug Repurposing for Allergies.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mast cells (MCs) participate in inflammation and pathological processes such as type I hypersensitivity. They can recognize type E immunoglobulins (IgE)-coupled allergens through the high-affinity receptors for IgE (FcεRI) membrane receptor, inducing the activation of a signaling pathway in which molecules such as spleen tyrosine kinase (SyK), Bruton's tyrosine kinase (BTK), and phospholipase Cy2 (PLCγ2) participate, promoting MC degranulation by promoting calcium mobilization. Valproic acid (VPA) selectively decreases PLCγ2 phosphorylation without impacting SyK kinase activity. Although BTK acts in parallel to SyK by phosphorylating PLCγ2, it has not been demonstrated whether VPA directly affects BTK. For this reason, the purpose of this work is to evaluate the interaction of BTK with VPA in an in silico molecular coupling analysis. Three-dimensional (3D) models of the ligand and receptor were selected to evaluate coupling with the support of bioinformatics tools, compared with a reference drug. Our results indicate that VPA binds favorably to BTK near its catalytic site. This binding is distinct from irreversible inhibitors, suggesting its role as a reversible inhibitor of this enzyme.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.